Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMNESTROGEN vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis,Estrogen replacement therapy in female hypogonadism,Palliative treatment of advanced breast cancer in selected postmenopausal women,Palliative treatment of advanced prostate cancer
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Hepatic metabolism via cytochrome P450 enzymes (CYP3A4 and others); undergoes enterohepatic recirculation.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
98% bound primarily to albumin and sex hormone-binding globulin (SHBG).
98% bound to sex hormone-binding globulin (SHBG) and albumin.
1.0-1.5 L/kg; indicates extensive tissue distribution and binding.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Oral: 2-10% due to first-pass metabolism; IM: 100%; Transdermal: 5-15%; Vaginal: 5-25%.
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
No specific dose adjustment required; use with caution in severe impairment (e GFR <30 m L/min/1.73m²) due to potential fluid retention
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
Contraindicated in Child-Pugh class B and C; for class A, use lowest effective dose with monitoring
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Not indicated for pediatric use; safety and efficacy not established
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Use lowest effective dose for shortest duration; increased risk of stroke, dementia, and breast cancer; consider alternative therapies
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Estrogen-progestin therapy increases the risk of cardiovascular events, breast cancer, and probable dementia. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Cardiovascular disorders (stroke, MI, thromboembolism), malignant neoplasms (endometrial cancer, breast cancer), probable dementia (use >65 years), gallbladder disease, hypercalcemia, visual abnormalities, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, fluid retention, hypothyroidism, exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and conditions aggravated by fluid retention.
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except selected patients), known or suspected estrogen-dependent neoplasia, active DVT/PE or history of thromboembolic disorders, known protein C, protein S, or antithrombin deficiency, known thrombophilic disorders, active or recent arterial thromboembolic disease (e.g., stroke, MI), known liver impairment or disease, known hypersensitivity to any ingredient.
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Grapefruit and grapefruit juice may increase estrogen levels; avoid large amounts. No significant food interactions reported but take with or without food consistently to maintain stable absorption.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalities, feminization of male fetus, and potential long-term reproductive effects. Use contraindicated in pregnancy.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Contraindicated during breastfeeding. Amnestrogen is excreted in breast milk; M/P ratio unknown. Potential for serious adverse effects in nursing infants including hormonal disruption.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
Not applicable as drug is contraindicated in pregnancy. No dose adjustment recommended due to avoidance of use.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
Amnestrogen (estrogen-progestin combination) is used for hormone replacement therapy. Monitor for thromboembolic events; avoid in patients with history of DVT/PE. Use lowest effective dose for shortest duration. Not for use in pregnancy; contraindicated in breast cancer. May increase risk of endometrial cancer if used without progestin in women with intact uterus.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Take exactly as prescribed; do not skip doses.,Report immediately any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or vision changes.,Avoid smoking while on this medication; increases clot risk.,Do not use during pregnancy; if pregnancy occurs, stop and contact doctor.,Regular breast exams and mammograms are recommended.,May cause nausea; take with food or at bedtime.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMNESTROGEN vs ANDROID 5, answered by our medical review team.
AMNESTROGEN is a Estrogen that works by Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMNESTROGEN and ANDROID 5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMNESTROGEN is: 1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMNESTROGEN and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMNESTROGEN is classified as Category C. First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalitie. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.